Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research at AdventHealth Central Florida, Professor of Medicine at the University of Central Florida, and at Loma Linda University Health, shared a post on LinkedIn:
“New Drug Development program presentations at ESMO25.
Our program continues to grow robustly with an ever-expanding portfolio of exciting trials coupled with a presence at major conferences.
We have coauthored 2 mini-oral presentations and a poster at ESMO25:
1) Invikafusp-alfa Marengo Therapeutics,
2) LY3866288 (Vepugratinib) Eli Lilly and Company,
3) KO-2806 Kura Oncology, Inc.
Thanks to collaborators, coinvestigators, sub-investigators and our team.”
More posts featuring Guru Sonpavde